"IonQ (IONQ) expects third quarter revenue of $27M and full year 2025 revenue of $91M, more than doubling sales year over year. IonQ raised $1B in equity and holds $1.6B in cash, making it the best capitalized pure play quantum computing company. IonQ's collaboration with AstraZeneca and NVIDIA delivered a 20x performance boost in drug development workflows, demonstrating practical quantum utility. Nvidia made early investors rich, but there is a new class of 'Next Nvidia Stocks' that could be even better; learn more here."
"What to Expect When IonQ Reports Revenue: $26.99 million EPS (GAAP): -$0.44 Analyst Range: Revenue $26.9 million-$27.07 million; EPS -$0.64 to -$0.35 Year-Ago EPS: -$0.24 Looking further ahead, analysts expect full-year 2025 revenue of $91.23 million with a loss of $1.68 per share, widening slightly to -$1.75 EPS on $171.71 million in 2026 sales. Despite steep losses, IonQ's sales are projected to more than double this year and again next year-an indication of growing commercial adoption."
IonQ projects third-quarter revenue near $27 million and full-year 2025 revenue of about $91 million, signaling more than a doubling of sales year over year. The company completed a $1 billion equity raise and holds roughly $1.6 billion in cash, making it the best-capitalized pure-play quantum computing firm. Strategic partnerships with AstraZeneca and NVIDIA produced a reported 20x performance boost in drug-development workflows. Analysts forecast widening GAAP losses even as revenue climbs, with 2025 EPS around -$1.68 and projected 2026 sales near $171.7 million. The company is expanding into quantum networking and pursuing an ambitious technology roadmap.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]